Results 11 to 20 of about 33,699 (271)

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study [PDF]

International Journal of COPD, 2022
Enrico de Nigris,1 Catrin Treharne,2 Nick Brighton,2 Ulf Holmgren,3 Andrew Walker,4 John Haughney5 1Formerly of Global Product and Portfolio Strategy, AstraZeneca, Cambridge, UK; 2Formerly of Health Economic Modelling, Regulatory and Access, Parexel ...
de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J   +5 more
doaj   +4 more sources

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD [PDF]

ERJ Open Research, 2020
Inhaled corticosteroid/long-acting β2-agonist combination therapy is a recommended treatment option for patients with chronic obstructive pulmonary disease (COPD) and increased exacerbation risk, particularly those with elevated blood eosinophil levels ...
Nicola A. Hanania, Alberto Papi, Antonio Anzueto, Fernando J. Martinez, Kimberly A. Rossman, Christy S. Cappelletti, Elizabeth A. Duncan, Jack S. Nyberg, Paul M. Dorinsky   +8 more
doaj   +4 more sources

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial [PDF]

Respiratory Research
Background The single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) is available for maintenance therapy of chronic obstructive pulmonary disease (COPD).
Henrik Watz, Anne-Marie Kirsten, Andrea Ludwig-Sengpiel, Matthias Krüll, Robert M. Mroz, George Georges, Guido Varoli, Rémi Charretier, Mauro Cortellini, Andrea Vele, Dmitry Galkin   +10 more
doaj   +3 more sources

Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial

ERJ Open Research
Background COPD and cardiovascular disease (CVD) are leading causes of death with overlapping and syndemic pathophysiological interactions. Inhaled triple therapies containing inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and ...
Fernando J. Martinez, John R. Hurst, MeiLan K. Han, David Price, Jinping Zheng, David D. Berg, Michel Pszczol, Mona Bafadhel, Carolyn S.P. Lam, Martin Fredriksson, Martin R. Cowie, Niki Arya, Karin Bowen, Alec Mushunje, Mehul Patel   +14 more
doaj   +3 more sources

Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study

COPD
The fixed-dose combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) delivered via pressurised metered-dose inhaler (pMDI) has demonstrated efficacy in chronic obstructive pulmonary disease (COPD), in studies predominantly conducted in ...
Fuqiang Wen, Yanmin Wu, Chunyan Xing, Yingqun Zhu, Yongxing Chen, Xiaodong Mei, Massimo Corradi, Glauco Cappellini, Emanuele Calabro, Sergio Amodio, Cissy Zhu, Dmitry Galkin   +11 more
doaj   +4 more sources

Budesonide-Glycopyrronium-Formoterol Fumarate Dihydrate (Breztri Aerosphere)

Canadian Journal of Health Technologies, 2021
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
Reimbursement Team
openalex   +4 more sources

Equivalência farmacêutica da formulação combinada de budesonida e formoterol em cápsula única com dispositivo inalador de pó Pharmaceutical equivalence of the combination formulation of budesonide and formoterol in a single capsule with a dry powder inhaler [PDF]

Jornal Brasileiro de Pneumologia, 2012
OBJETIVO: Avaliar a equivalência farmacêutica da formulação teste (associação fixa de budesonida e fumarato de formoterol em cápsula única dispensada com o dispositivo Aerocaps®) em relação a uma formulação referência (budesonida e fumarato de formoterol
Marina Andrade-Lima, Luiz Fernando Ferreira Pereira, Ana Luisa Godoy Fernandes   +2 more
doaj   +5 more sources

Real-World Efficacy of Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium on Diaphragmatic Workload Assessed by Ultrasound and Lung Function in Patients with Uncontrolled Asthma. [PDF]

Adv Respir Med
Highlights What are the main findings? Triple inhaled therapy with beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) significantly improved airflow, reduced residual volume, and enhanced symptom control in patients with ...
Maiorano A, Ferrante Bannera A, Lupia C, Pastore D, Chiarella E, Piazzetta GL, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +9 more
europepmc   +2 more sources

Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial [PDF]

Therapeutic Advances in Respiratory Disease, 2018
Background: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform ® ; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide ® Evohaler ® pMDI; 100 ...
Anna Płoszczuk, Miroslava Bosheva, Kay Spooner, Tammy McIver, Sanjeeva Dissanayake   +4 more
doaj   +2 more sources

Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/Formoterol Fumarate in General Practice in England. [PDF]

Adv Ther
We compared the real-world effectiveness of initiating beclometasone dipropionate/formoterol fumarate (BDP/FOR) versus fluticasone furoate/vilanterol (FF/VI) in a general practice (GP) asthma cohort in England.
Woodcock A, Blakey J, Bourdin A, Canonica GW, Domingo C, Ford A, Hulme R, Tritton T, Palomares I, Sadhu S, Biswas A, Verma M.   +11 more
europepmc   +2 more sources